STAT+: Despite Novo drug's failure, cardiologists say they will still pursue anti-inflammatories
Despite a Novo drug's failure, cardiologists say they will still pursue anti-inflammatories. They argue that the negative results do not invalidate that inflammation plays a very important role in cardiovascular disease.
AI summary · generated only from source feed metadata; consult originalSource published
Published here
views4
Original source
STAT — Biotech
Media report · consult original reporting
Read the original ↗https://www.statnews.com/2026/11/07/aha-2026-conference-novo-nordisk-zeus-trial-ziltivekimab-results/Original headline
STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories
AI bilingual edit · consult originalHeadlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.